Trial Profile
Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 30 Jul 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT00082381).
- 05 Nov 2010 New trial record.